The press service of Roszdravnadzor reported that the supply to Russia of another Danish drug for diabetes will be stopped. DEA News.
As noted in the department, in November 2022, the Danish company Novo Nordisk officially informed Roszdravnadzor that from 2024 it will stop the supply of the drug Rebelsas (INN Semaglutide).
The press service said that in the three months of 2023, 9,240 packages of this drug went into civil circulation, deliveries will be made by the end of this year.
The drug “Rebelsas” (active ingredient semaglutide) was registered in the Russian Federation in 2021, it is intended for use in adult patients with type 2 diabetes.
As noted in Roszdravnadzor, this drug has analogues in the Russian pharmaceutical market.
Previously reported Novo Nordisk stopped deliveries Popular drug “Ozempik” for diabetes to Russia.